Home » Stocks » AtriCure

AtriCure, Inc. (ATRC)

Stock Price: $40.41 USD -0.37 (-0.91%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.82B
Revenue (ttm) 211.98M
Net Income (ttm) -50.10M
Shares Out 44.93M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $40.41
Previous Close $40.78
Change ($) -0.37
Change (%) -0.91%
Day's Open 40.77
Day's Range 40.10 - 41.15
Day's Volume 227,656
52-Week Range 22.57 - 51.76

More Stats

Market Cap 1.82B
Enterprise Value 1.66B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.93M
Float 43.54M
EPS (basic) -1.3
EPS (diluted) -1.28
FCF / Share -1.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.31M
Short Ratio 4.74
Short % of Float 4.09%
Beta 0.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.57
PB Ratio 4.40
Revenue 211.98M
Operating Income -46.70M
Net Income -50.10M
Free Cash Flow -44.39M
Net Cash 157.69M
Net Cash / Share 3.51
Gross Margin 80.35%
Operating Margin -22.03%
Profit Margin -23.60%
FCF Margin -20.94%
ROA -5.83%
ROE -15.22%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$55.62*
(37.64% upside)
Low
50.0
Current: $40.41
High
63.0
Target: 55.62
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue23120217515513010781.8970.2564.4059.01
Revenue Growth14.47%15.4%12.64%19.54%20.75%31.22%16.57%9.08%9.14%-
Gross Profit17014712611192.8875.7559.5650.0147.0045.39
Operating Income-33.12-17.13-24.98-31.14-26.72-16.36-10.89-7.20-4.73-3.19
Net Income-35.19-21.14-26.89-33.34-27.21-16.21-11.46-7.53-5.46-3.79
Shares Outstanding37.5934.0932.3931.6128.0626.3720.4316.1915.6715.10
Earnings Per Share-0.94-0.62-0.83-1.05-0.97-0.61-0.56-0.47-0.35-0.25
Operating Cash Flow-15.81-4.17-8.94-15.12-7.84-21.60-5.22-1.94-1.99-0.03
Capital Expenditures-12.14-6.21-6.38-7.69-24.00-9.13-2.82-2.96-1.13-1.81
Free Cash Flow-27.95-10.38-15.33-22.81-31.84-30.73-8.04-4.90-3.12-1.84
Cash & Equivalents81.8012434.4544.0134.5859.6526.2112.0014.1812.57
Total Debt76.4252.4636.8637.2113.714.066.458.446.472.85
Net Cash / Debt5.3871.94-2.416.8020.8755.5919.763.567.719.72
Assets55835726827627315811232.4333.8633.72
Liabilities31110710710886.4125.8739.3419.9318.2416.98
Book Value24724916116818713372.6012.5015.6216.74
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AtriCure, Inc.
Country United States
Employees 730
CEO Michael H. Carrel

Stock Information

Ticker Symbol ATRC
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: ATRC
IPO Date August 5, 2005

Description

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.